Endless studies in the last decades lead to an immense progress of nowadays therapy regimes depending on clinical tumor subtype: from conventional e.g., surgery and chemotherapy to endocrine and targeted anti-tumor therapies e.g., tamoxifen and human epidermal growth factor receptor 2 (HER2)-blockade [3]. Here, ERBB2 is linked to neoplasm.